Effects of repeated treatment with haloperidol on rat striatal neutral endopeptidase, and on mu- and delta-opioid binding sites: comparison with chronic morphine and chronic kelatorphan.
Neutral endopeptidase (NEP) and mu- and delta-opioid receptor densities were measured in sections of rat striatum by in vitro radioautography with the selective ligands: 3 nM [3H]N-[(2RS)-3-hydroxyaminocarbonyl-2-benzyl-1-oxopropyl]glycine ([ 3H]HACBO-Gly), 3 nM [3H]Tyr-D.Ala-Gly-(NMe)Phe-Gly-ol ([ 3H]DAGO) and 3 nM [3H]Tyr-D-Thr-Gly-Phe-Leu-Thr ([ 3H]DTLET), respectively. Haloperidol treatment (2 mg/kg/day, i.p., 3 weeks), which has been reported to increase enkephalin levels in the striatum, induced a 23% decrease in striatal (posterior level A= +8.4-8.6 mm) NEP labeling (but no change of mu- and delta-sites). In contrast, no change in NEP occurred after chronic morphine (40-160 mg/kg/day, s.c., 4 days) or kelatorphan (10 nmol/h, i.c.v., 7 days), a mixed inhibitor of enkephalin-degrading peptidases.